source
- Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial missAstraZeneca reported that its experimental drug Wainua failed to meet its primary endpoints in a study of transthyretin amyloid cardiomyopathy (ATTR-CM). The setback raised concerns about the thera…
- Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 studyA Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…